Company: LRHC
Filing Date: 2025-09-29
Form Type: DEF 14C
Source: 0001213900-25-092610
Chunk: 14

Company: La Rosa Holdings Corp.
Filing Date: 2025-09-29
Form: DEF 14C
Chunk 14
---
 the Common Stock or voting power, becoming the largest ownership position, may trigger this requirement. |

| Ø | Nasdaq Listing Rule 5635(d) necessitates stockholder approval before any nonpublic offering involving the sale or potential sale of Common Stock (or convertible securities), equal to 20% or more of the pre-issuance Common Stock or voting power, at a price (“Minimum Price”) below the last close or the average closing price over the preceding five trading days. |

The potential for the shares
of Common Stock to be issued pursuant to the Facility at the price less than the Minimum Price invokes Nasdaq Listing Rule 5635(d). Assuming
issuance of all shares covered by the Amended Facility Agreement, such issuance could involve more than 20% of the number of shares of
our Common Stock outstanding at the time of issuance. This scenario would require prior stockholder approval under Nasdaq Listing Rule
5635(b).

The Majority Stockholders
Consent constitutes the only stockholder approval required under the NRS, Nasdaq’s 20% Rule, our Amended and Restated Articles of
Incorporation and our Bylaws, in order to provide the Stockholder Approval required under the Amended Facility Agreement.

The Stockholder Approval will not become effective until the date that
is twenty (20) calendar days after this Information Statement is first mailed or otherwise delivered to holders of our Common Stock as
of the Record Date, or until approximately October 19, 2025.

<div align='center'>7

EFFECTIVE DATE OF ACTION BY WRITTEN CONSENT</div>

Per Rule 14c-2 under the Exchange
Act, the corporate action taken by written consent becomes effective no earlier than twenty (20) calendar days after the first mailing
or delivery of this Information Statement to stockholders as of the Record Date. This Information Statement provides a comprehensive overview
of the actions approved by the holders of a majority of our outstanding Common Stock.

<div align='center'>DISSENTER’S RIGHTS OF APPRAISAL</div>

Stockholders do not have any
dissenter’s rights or appraisal rights in connection with the approval of the Corporate Action described in this Information Statement.

<div align='center'>OUTSTANDING VOTING SECURITIES</div>

Each share of Common Stock
grants one vote on each matter submitted to stockholders. Each share of Series X Super Voting Preferred Stock of the Company grants 10,000
Common Stock votes on each matter